Skip to content

EBIT at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$30.93M+27.9%
Immunome logo
ImmunomeIMNM
-$59.33M-32.9%
CG Oncology logo
CG OncologyCGON
-$66.39M-57.3%
Erasca, Inc. logo
Erasca, Inc.ERAS
-$187.91M-427%
Amgen logo
AmgenAMGN
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Calculated from Replimune Group’s reported figures.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's EBIT?
Replimune Group (REPL) reported EBIT of -$71.87M in Q4 2025.
How has Replimune Group's EBIT changed year-over-year?
Replimune Group's EBIT decreased by 8.9% year-over-year, from -$66.02M to -$71.87M.
What is the long-term trend for Replimune Group's EBIT?
Over 3 years (2022 to 2025), Replimune Group's EBIT has grown at a 30.3% compound annual growth rate (CAGR), from -$118.31M to -$261.63M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.